AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23825432 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 76
Study 23825432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslexic children matched for reading performance
Number of subjects: 76
Study 23825432 — intervention group
Group type: COMPARATOR
Intervention: Control children matched for reading performance
Number of subjects: 76
Study 21732049 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 200 min/week
Number of subjects: 160
Study 21732049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 19521272 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations of treatment (baseline expectations)
Number of subjects: 100
Study 19521272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulfillment of expectations
Number of subjects: 100
Study 19521272 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual improvement recorded at 12 months
Number of subjects: 100
Study 16904480 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (group 1; 88 patients)
Number of subjects: 178
Study 16904480 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (group 1)
Number of subjects: 178
Study 16904480 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2; 90 patients)
Number of subjects: 178
Study 16904480 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 178
Study 15639690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride plus rosiglitazone
Number of subjects: 40
Study 15639690 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus rosiglitazone
Number of subjects: 40
Study 11582584 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I)
Number of subjects: 34
Study 11582584 — intervention group
Group type: EXPERIMENTAL
Intervention: Palladium-103 (103Pd)
Number of subjects: 34
Study 11582584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 34
Study 11582584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate brachytherapy
Number of subjects: 34
Study 9441100 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiacetazone-containing regimen
Number of subjects: 119
Study 9441100 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin-containing regimen
Number of subjects: 119
Study 9441100 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > or = 30 years
Number of subjects: 119
Study 9441100 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular compliance
Number of subjects: 119
Study 7973221 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular test
Number of subjects: 0
Study 7973221 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent data monitoring committees
Number of subjects: 0
Study 2453619 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (PVeBV)
Number of subjects: 52
Study 2453619 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy regimen (PVeB)
Number of subjects: 52
Study 31177388 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cerebellar transcranial direct current stimulation (tDCS)
Number of subjects: 26
Study 31177388 — intervention group
Group type: COMPARATOR
Intervention: Sham cerebellar transcranial direct current stimulation (tDCS)
Number of subjects: 26
Study 29871240 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic resonance therapy combined with systemic steroid therapy and conventional drug therapy
Number of subjects: 128
Study 29871240 — intervention group
Group type: COMPARATOR
Intervention: Steroid therapy and conventional drug therapy
Number of subjects: 128
Study 29871240 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic resonance therapy combined with systemic steroid therapy
Number of subjects: 128
Study 25433294 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual CPR feedback
Number of subjects: 324
Study 25433294 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-Time (JIT) CPR training
Number of subjects: 324
Study 25433294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of real-time feedback and JIT CPR training
Number of subjects: 324
Study 25433294 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 324
Study 25433294 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback
Number of subjects: 324
Study 23250834 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day for 14 days)
Number of subjects: 30
Study 23250834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23250834 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 30
Study 23250834 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Placebo
Number of subjects: 30
Study 21571595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 48
Study 21571595 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 48
Study 17935001 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal intervening tasks (WAIS‐III Vocabulary or Peabody Picture Vocabulary Test ‐ IIIB)
Number of subjects: 120
Study 17935001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal intervening tasks (Raven's Standard Progressive Matrices or WAIS‐III Block Design)
Number of subjects: 120
Study 17243888 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative hypnosis
Number of subjects: 10
Study 17243888 — intervention group
Group type: COMPARATOR
Intervention: Nonhypnosis (epidural catheter and narcotics)
Number of subjects: 10
Study 15380496 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 78
Study 15380496 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 78
Study 11580734 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) treatment with low-caloric diet and insulin when appropriate
Number of subjects: 622
Study 11580734 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care (Control group)
Number of subjects: 622
Study 9613271 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable performance systems
Number of subjects: 10
Study 9613271 — intervention group
Group type: COMPARATOR
Intervention: Constant performance system
Number of subjects: 10
Study 9613271 — intervention group
Group type: EXPERIMENTAL
Intervention: Large nasal catheter
Number of subjects: 10
Study 9613271 — intervention group
Group type: EXPERIMENTAL
Intervention: Venturi mask
Number of subjects: 10
Study 7859806 — intervention group
Group type: EXPERIMENTAL
Intervention: GR122311X 500 mg bid (301 mg bismuth per day)
Number of subjects: 48
Study 7859806 — intervention group
Group type: EXPERIMENTAL
Intervention: GR122311X 1.0 g bid (602 mg bismuth per day)
Number of subjects: 48
Study 7859806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) 240 mg bid (431 mg bismuth per day)
Number of subjects: 48
Study 7859806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2510661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 6
Study 2510661 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 6
Study 2510661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg) + Propranolol (80 mg)
Number of subjects: 6
Study 2510661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 16219589 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprevention (Tamoxifen or Raloxifene)
Number of subjects: 51
Study 16219589 — intervention group
Group type: COMPARATOR
Intervention: Non-participation in chemoprevention
Number of subjects: 51
Study 31785779 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to di (2‐ethylhexyl), butyl‐benzyl and di‐isobutyl phthalates (DEHP, BBzP, DiBP)
Number of subjects: 80
Study 31785779 — intervention group
Group type: EXPERIMENTAL
Intervention: DEHP, BBzP, and DiBP exposure
Number of subjects: 80
Study 31622137 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) with pasable
Number of subjects: 3261
Study 31622137 — intervention group
Group type: COMPARATOR
Intervention: Self-rated health (SRH) with regular
Number of subjects: 3261
Study 27096538 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (sequential delivery of IPL and Nd:YAG laser)
Number of subjects: 24
Study 27096538 — intervention group
Group type: COMPARATOR
Intervention: Separated therapy (IPL followed by Nd:YAG treatment 3 days later)
Number of subjects: 24
Study 26682290 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream 3.75% applied once daily until complete clearance or a maximum of 8 weeks
Number of subjects: 447
Study 26682290 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream 2.5% applied once daily until complete clearance or a maximum of 8 weeks
Number of subjects: 447
Study 26682290 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied once daily until complete clearance or a maximum of 8 weeks
Number of subjects: 447
Study 22925000 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin ultrasensitive-guided antibiotic treatment
Number of subjects: 200
Study 22925000 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke unit care
Number of subjects: 200
Study 22048577 — intervention group
Group type: EXPERIMENTAL
Intervention: TCP alone
Number of subjects: 39
Study 22048577 — intervention group
Group type: EXPERIMENTAL
Intervention: TCP + CA
Number of subjects: 39
Study 22048577 — intervention group
Group type: EXPERIMENTAL
Intervention: TCP + CA + ORC
Number of subjects: 39
Study 19536974 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent RCTs of psychotherapy
Number of subjects: 0
Study 16878192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg)
Number of subjects: 29
Study 16878192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15238624 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic laser surgery
Number of subjects: 142
Study 15238624 — intervention group
Group type: COMPARATOR
Intervention: Serial amnioreduction
Number of subjects: 142
Study 11534893 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 0
Study 9240876 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positive diabetic subjects
Number of subjects: 69
Study 9240876 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study 9240876 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects with anti-cow's milk protein positivity
Number of subjects: 69
Study 9240876 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects studied within 3 months of diabetes onset
Number of subjects: 69
Study 9240876 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects with asymptomatic Helicobacter pylori infection
Number of subjects: 69
Study 8214664 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 21
Study 8214664 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg/kg
Number of subjects: 21
Study 3610017 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 646 (800-1000 mcg)
Number of subjects: 10
Study 3610017 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 646 (500 mcg)
Number of subjects: 10
Study 3610017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29961438 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal lamella relaxing incision
Number of subjects: 32
Study 29961438 — intervention group
Group type: COMPARATOR
Intervention: Combined conventional medialisation and controlled synechiae
Number of subjects: 32
Study 28162913 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-led preventive training program (PTP)
Number of subjects: 89
Study 25945112 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural Integration (SI) plus outpatient rehabilitation (OR)
Number of subjects: 46
Study 25945112 — intervention group
Group type: COMPARATOR
Intervention: Outpatient rehabilitation (OR) alone
Number of subjects: 46
Study 23834406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis + CD (hypnotherapist guided)
Number of subjects: 448
Study 23834406 — intervention group
Group type: EXPERIMENTAL
Intervention: CD only (nurse administered)
Number of subjects: 448
Study 23834406 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional intervention or CDs)
Number of subjects: 448
Study 20642944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool phacoemulsification technique
Number of subjects: 100
Study 20642944 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification technique
Number of subjects: 100
Study 19060515 — intervention group
Group type: EXPERIMENTAL
Intervention: hylan G‐F 20 (Synvisc), 2 ml, three intra-articular injections
Number of subjects: 45
Study 19060515 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate (Hyalgan), 2 ml, five intra-articular injections
Number of subjects: 45
Study 19060515 — intervention group
Group type: COMPARATOR
Intervention: No injections (controls)
Number of subjects: 45
Study 16903964 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial shock conversion efficacy for spontaneous AT/AF episodes
Number of subjects: 95
Study 16903964 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial shock conversion efficacy for induced AT/AF episodes
Number of subjects: 95
Study 16903964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean detection time with new features ON
Number of subjects: 95
Study 16903964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean detection time with new features OFF
Number of subjects: 95
Study 16903964 — intervention group
Group type: COMPARATOR
Intervention: Randomized crossover trial of atrial preventative pacing features
Number of subjects: 95
Study 14528774 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser alone
Number of subjects: 60
Study 14528774 — intervention group
Group type: COMPARATOR
Intervention: Laser followed by etching
Number of subjects: 60
Study 11004650 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐2 high‐velocity, low‐amplitude manipulation
Number of subjects: 13
Study 8977237 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 26
Study 8977237 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) plus stem cell factor (SCF)
Number of subjects: 26
Study 8977237 — intervention group
Group type: EXPERIMENTAL
Intervention: Flk-2/Flt3 ligand (FL) plus IL-3
Number of subjects: 26
Study 1613122 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1 mg/kg
Number of subjects: 0
Study 1613122 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 5 mg/kg
Number of subjects: 0
Study 1613122 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 15 mg/kg
Number of subjects: 0
Study 1613122 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 0
Study 6690170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nalbuphine, 15 mg (N = 39)
Number of subjects: 121
Study 6690170 — intervention group
Group type: COMPARATOR
Intervention: Codeine, 60 mg (N = 42)
Number of subjects: 121
Study 6690170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 40)
Number of subjects: 121
Study 6690170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nalbuphine (N = 39)
Number of subjects: 121
Study 6690170 — intervention group
Group type: COMPARATOR
Intervention: Codeine (N = 42)
Number of subjects: 121
Study 6690170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active drugs
Number of subjects: 121
Study 6690170 — intervention group
Group type: EXPERIMENTAL
Intervention: New parameters
Number of subjects: 121
Study 31899888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + 12.5% energy intake reduction
Number of subjects: 0
Study 31899888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29523129 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video-assisted informed consent
Number of subjects: 142
Study 29523129 — intervention group
Group type: COMPARATOR
Intervention: Conventional informed consent (reading an informed consent document)
Number of subjects: 142
Study 26350171 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate for 10 years
Number of subjects: 0
Study 26350171 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (6 annual infusions)
Number of subjects: 0
Study 26350171 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of oral BP treatment for up to 10 years
Number of subjects: 0
Study 26350171 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of intravenous BP treatment for up to 6 years
Number of subjects: 0
Study 26350171 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug holiday of 2 to 3 years after 3 to 5 years of BP treatment
Number of subjects: 0
Study 24477080 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued use of tiotropium, salmeterol, and fluticasone
Number of subjects: 2456
Study 24477080 — intervention group
Group type: COMPARATOR
Intervention: Stepwise withdrawal of fluticasone
Number of subjects: 2456
Study 24477080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ICS and withdrawal)
Number of subjects: 2456
Study 22252366 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vitamin E in crude soybean oil diet
Number of subjects: 480
Study 22252366 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregano essential oil in crude soybean oil diet
Number of subjects: 480
Study 22252366 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg vitamin E in crude soybean oil diet
Number of subjects: 480
Study 22252366 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregano essential oil in acidulated soybean oil soapstock diet
Number of subjects: 480
Study 22252366 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vitamin E in acidulated soybean oil soapstock diet
Number of subjects: 480
Study 22252366 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg vitamin E in acidulated soybean oil soapstock diet
Number of subjects: 480
Study 20844469 — intervention group
Group type: EXPERIMENTAL
Intervention: KTR (Kidney Transplant Recipients)
Number of subjects: 106
Study 20844469 — intervention group
Group type: COMPARATOR
Intervention: CP (Control Patients)
Number of subjects: 106
Study 20844469 — intervention group
Group type: EXPERIMENTAL
Intervention: KTR treated with or without calcineurin inhibitors
Number of subjects: 106
Study 19171954 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept II model C (IIC) rowing ergometer
Number of subjects: 8
Study 19171954 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept II model D (IID) rowing ergometer
Number of subjects: 8
Study 16047526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 102
Study 12196460 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg/day)
Number of subjects: 20
Study 12196460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11767274 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout intervention program (19 participants)
Number of subjects: 171
Study 11767274 — intervention group
Group type: COMPARATOR
Intervention: Control group (73 dentists)
Number of subjects: 171
Study 11767274 — intervention group
Group type: COMPARATOR
Intervention: Control group (not taking preventive action)
Number of subjects: 171
Study 9278803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg, droperidol 0.03 mg/kg, diazepam 0.06 mg/kg
Number of subjects: 80
Study 9278803 — intervention group
Group type: COMPARATOR
Intervention: Control group (same drugs except for ketamine)
Number of subjects: 80
Study 8444625 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program designed to reduce low back injuries, taught by physical therapists for 3 hours, with reinforcement every 6 months.
Number of subjects: 4000
Study 8444625 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental unit workers who received training.
Number of subjects: 4000
Study 8444625 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained experimental unit workers).
Number of subjects: 4000
Study 3541426 — intervention group
Group type: EXPERIMENTAL
Intervention: ID-1 group (3 doses of 0.1 ml intradermally at 0, 1 month, and 4 months)
Number of subjects: 63
Study 3541426 — intervention group
Group type: EXPERIMENTAL
Intervention: ID-2 group (2 doses of 0.2 ml intradermally at 0 and 1 dose of 0.1 ml at 4 months)
Number of subjects: 63
Study 3541426 — intervention group
Group type: COMPARATOR
Intervention: IM group (3 doses of 1.0 ml intramuscularly at 0, 1 month, and 4 months)
Number of subjects: 63
Study 28474871 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen rich water (HRW)
Number of subjects: 8
Study 28474871 — intervention group
Group type: COMPARATOR
Intervention: Placebo normal water (PLA)
Number of subjects: 8
Study 28474871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (HRW and PLA)
Number of subjects: 8
Study 27209463 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (counselling on diet, physical activity, and weight control)
Number of subjects: 226
Study 27209463 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (control group)
Number of subjects: 226
Study 24817694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone delivered intervention (HEART; n = 85) plus usual care
Number of subjects: 171
Study 24817694 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n = 86)
Number of subjects: 171
Study 23975447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicar
Number of subjects: 33
Study 23975447 — intervention group
Group type: COMPARATOR
Intervention: Control (No Amicar)
Number of subjects: 33
Study 20873604 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bazhengsan
Number of subjects: 72
Study 20873604 — intervention group
Group type: COMPARATOR
Intervention: Primal Bazhengsan (Control)
Number of subjects: 72
Study 18254432 — intervention group
Group type: EXPERIMENTAL
Intervention: Education training
Number of subjects: 51
Study 18254432 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 51
Study 18254432 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51